Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ

$47.28

+$0.12 (0.25%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$46.76$47.80

Open $47.23

52 Week Range

$29.16$57.65

Previous Close $47.16

Market Cap2.65B

Volume597.49K

Avg Volume852.23K

P/E (TTM)-139.87

EPS (TTM)$-0.34

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Supernus Pharmaceuticals, Inc.

DEC32025

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

Source: GlobeNewsWire•12 days ago

ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced toda...

NOV212025

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

Source: GlobeNewsWire•24 days ago

ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced toda...

NOV122025

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Source: GlobeNewsWire•33 days ago

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced toda...

NOV42025

Supernus Announces Third Quarter 2025 Financial Results

Source: GlobeNewsWire•41 days ago

ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announce...

OCT212025

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Source: GlobeNewsWire•55 days ago

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announce...